| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/IJC.29918 |
| P8608 | Fatcat ID | release_kabnakxjkjbhdi6fimnzg6emru |
| P698 | PubMed publication ID | 26547270 |
| P5875 | ResearchGate publication ID | 283577226 |
| P2093 | author name string | Svetlana Bunimovich-Mendrazitsky | |
| Alex Kiselyov | |||
| Vladimir Startsev | |||
| P2860 | cites work | Genome sequencing identifies a basis for everolimus sensitivity | Q24631915 |
| Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib | Q27852954 | ||
| Comprehensive molecular characterization of urothelial bladder carcinoma | Q28306864 | ||
| Expression of OCT4A: the first step to the next stage of urothelial bladder cancer progression | Q28396049 | ||
| MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer | Q29617772 | ||
| Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75. | Q33394575 | ||
| Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy | Q33572016 | ||
| p63 expression defines a lethal subset of muscle-invasive bladder cancers | Q34131185 | ||
| Increased expression of MMP-9 and IL-8 are correlated with poor prognosis of Bladder Cancer | Q34303116 | ||
| Cellular origin of bladder neoplasia and tissue dynamics of its progression to invasive carcinoma | Q34338401 | ||
| Twist1 and Y-box-binding protein-1 are potential prognostic factors in bladder cancer. | Q39197304 | ||
| Glycogen synthase kinase-3beta: a prognostic marker and a potential therapeutic target in human bladder cancer | Q39648631 | ||
| FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder | Q43115752 | ||
| Human leukocyte antigen class I down-regulation in muscle-invasive bladder cancer: its association with clinical characteristics and survival after cystectomy | Q44803679 | ||
| Enhanced stromal syndecan-1 expression is an independent risk factor for poor survival in bladder cancer | Q46159727 | ||
| Absent CD44v6 expression is an independent predictor of poor urothelial bladder cancer outcome | Q46188649 | ||
| Inhibition of STAT signalling in bladder cancer by diindolylmethane: relevance to cell adhesion, migration and proliferation | Q46223881 | ||
| Hybrid discrete-continuous model of invasive bladder cancer. | Q47883526 | ||
| The molecular background of urothelial cancer: ready for action? | Q53232865 | ||
| CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma. | Q53272755 | ||
| TRAIL and osteoprotegerin (OPG) expression in bladder urothelial carcinoma: correlation with clinicopathological parameters and prognosis. | Q53850058 | ||
| Expression and function role of DNA methyltransferase 1 in human bladder cancer. | Q54594046 | ||
| Significance of ERBB2 overexpression in therapeutic resistance and cancer-specific survival in muscle-invasive bladder cancer patients treated with chemoradiation-based selective bladder-sparing approach. | Q55070725 | ||
| Prognostic and clinicopathological significance of survivin expression in bladder cancer patients: a meta-analysis | Q56524160 | ||
| B domain containing Tenascin-C: A new urine marker for surveillance of patients with urothelial carcinoma of the urinary bladder? | Q57911992 | ||
| Stratification based on methylation of TBX2 and TBX3 into three molecular grades predicts progression in patients with pTa-bladder cancer | Q58862326 | ||
| Association of hyaluronic acid family members (HAS1, HAS2, and HYAL‐1) with bladder cancer diagnosis and prognosis | Q34512129 | ||
| Epigenetic inactivation of ST6GAL1 in human bladder cancer | Q34695132 | ||
| ARID1A alterations are associated with FGFR3-wild type, poor-prognosis, urothelial bladder tumors. | Q34708383 | ||
| The combinatorial complexity of cancer precision medicine | Q34781332 | ||
| Overexpression of YAP 1 contributes to progressive features and poor prognosis of human urothelial carcinoma of the bladder | Q34840601 | ||
| Interleukin-4 receptor alpha overexpression in human bladder cancer correlates with the pathological grade and stage of the disease | Q34982602 | ||
| Mammalian target of rapamycin complex 2 (mTORC2) is a critical determinant of bladder cancer invasion | Q35060424 | ||
| A cell of origin gene signature indicates human bladder cancer has distinct cellular progenitors | Q35072270 | ||
| Targeting the Hedgehog pathway in cancer | Q35076275 | ||
| Loss of FOXA1 Drives Sexually Dimorphic Changes in Urothelial Differentiation and Is an Independent Predictor of Poor Prognosis in Bladder Cancer | Q35568071 | ||
| Hedgehog pathway activation in human transitional cell carcinoma of the bladder | Q35832354 | ||
| Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer. | Q35860815 | ||
| Aldehyde dehydrogenase 1 A1-positive cell population is enriched in tumor-initiating cells and associated with progression of bladder cancer | Q36529700 | ||
| The p63 protein isoform ΔNp63α inhibits epithelial-mesenchymal transition in human bladder cancer cells: role of MIR-205. | Q36579525 | ||
| Interleukin-20 promotes migration of bladder cancer cells through extracellular signal-regulated kinase (ERK)-mediated MMP-9 protein expression leading to nuclear factor (NF-κB) activation by inducing the up-regulation of p21(WAF1) protein expressio | Q36635881 | ||
| Loss of Sh3gl2/endophilin A1 is a common event in urothelial carcinoma that promotes malignant behavior | Q36945929 | ||
| Response classification based on a minimal model of glioblastoma growth is prognostic for clinical outcomes and distinguishes progression from pseudoprogression | Q37088426 | ||
| Constitutive β-catenin activation induces male-specific tumorigenesis in the bladder urothelium | Q37215956 | ||
| Prediction of drug response in breast cancer using integrative experimental/computational modeling | Q37288570 | ||
| SIP1 protein protects cells from DNA damage-induced apoptosis and has independent prognostic value in bladder cancer. | Q37329523 | ||
| Novel role of MDA-9/syntenin in regulating urothelial cell proliferation by modulating EGFR signaling. | Q37412627 | ||
| Urinary EpCAM in urothelial bladder cancer patients: characterisation and evaluation of biomarker potential | Q37558983 | ||
| Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology | Q37612632 | ||
| EIF5A2 predicts outcome in localised invasive bladder cancer and promotes bladder cancer cell aggressiveness in vitro and in vivo | Q37681730 | ||
| Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer | Q38222834 | ||
| Predictive markers in bladder cancer: do we have molecular markers ready for clinical use? | Q38230912 | ||
| Molecular markers for urothelial bladder cancer prognosis: toward implementation in clinical practice | Q38248822 | ||
| Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity | Q38297729 | ||
| Galectin-3 expression is associated with bladder cancer progression and clinical outcome | Q38344767 | ||
| Nuclear cIAP1 overexpression is a tumor stage- and grade-independent predictor of poor prognosis in human bladder cancer patients | Q38409089 | ||
| Interleukin-5 enhances the migration and invasion of bladder cancer cells via ERK1/2-mediated MMP-9/NF-κB/AP-1 pathway: involvement of the p21WAF1 expression | Q38449433 | ||
| Significance of 4E-binding protein 1 as a therapeutic target for invasive urothelial carcinoma of the bladder | Q38916793 | ||
| Methylation-mediated silencing of Dlg5 facilitates bladder cancer metastasis | Q38931960 | ||
| A new tumor suppressor role for the Notch pathway in bladder cancer | Q38959215 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | bladder carcinoma | Q18556149 |
| P304 | page(s) | 2562-2569 | |
| P577 | publication date | 2015-11-06 | |
| P1433 | published in | International Journal of Cancer | Q332492 |
| P1476 | title | Key signaling pathways in the muscle-invasive bladder carcinoma: Clinical markers for disease modeling and optimized treatment | |
| P478 | volume | 138 |
| Q49798105 | Benzidine Induces Epithelial-Mesenchymal Transition of Human Bladder Cancer Cells through Activation of ERK5 Pathway |
| Q47406043 | Distinct TP63 Isoform-Driven Transcriptional Signatures Predict Tumor Progression and Clinical Outcomes. |
| Q39665461 | Enzalutamide inhibits androgen receptor-positive bladder cancer cell growth. |
| Q52728659 | Epidermal growth factor receptor function in the human urothelium. |
| Q33844635 | Heterogeneous nuclear ribonucleoprotein K is associated with poor prognosis and regulates proliferation and apoptosis in bladder cancer |
| Q52657721 | Identification of Differentially Expressed Genes between Original Breast Cancer and Xenograft Using Machine Learning Algorithms. |
| Q33591719 | Implication of vascular endothelial growth factor A and C in revealing diagnostic lymphangiogenic markers in node-positive bladder cancer |
| Q38694277 | MET/SMAD3/SNAIL circuit mediated by miR-323a-3p is involved in regulating epithelial-mesenchymal transition progression in bladder cancer |
| Q37363467 | Simple and Efficient Stratification of Invasive Bladder Cancer Patients |
| Q49220712 | The current status and clinical value of circulating tumor cells and circulating cell-free tumor DNA in bladder cancer |
| Q93198763 | The role and function of PPARγ in bladder cancer |
| Q37619797 | ZKSCAN3 promotes bladder cancer cell proliferation, migration, and invasion |
Search more.